Spencer board OKs buyout

Spencer Pharmaceutical announced today that its board of directors is in favor of the buyout offer at $0.97 per share. The company has requested details from the acquirer as well as timeline and have requested that funds be transferred to an independent escrow agent. The company expects to release the name of the private equity fund on or before Nov. 19, and file appropriate supplemental information on the alternative reporting system of the OTC Markets. Spencer release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.